Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 13 - Targeting therapies in cancer: opportunities in ovarian cancer

  • from SECTION 3 - IMAGING AND THERAPY: STATE OF THE ART
  • Edited by Sean Kehoe, Richard J. Edmondson, Martin Gore, Iain A. McNeish
  • Book:
    Gynaecological Cancers
    Published online:
    05 February 2014
    Print publication:
    01 June 2011, pp 167-182

  • Summary

    This chapter outlines the recent advances in the molecular classification of ovarian cancer and the efforts for rationalised targeted therapies of molecular drivers of individual cancers with a particular emphasis on kinases and their inhibitors. It highlights the challenges that face targeting strategies, particularly at the interface between target discovery and validation that leads to the development of targeting agents. Development of small interfering RNA (siRNA) technology could provide a tool to overcome the shortcomings of some current therapeutic approaches. One of the challenges surrounding the use of siRNA for systemic therapy relates to the need for efficient and biocompatible delivery vehicles. Liposomes, in general, have been shown to be safe in a number of clinical trials using a wide variety of anti-cancer and antimicrobial drugs. Chitosan nanoparticles are highly effective for delivery of siRNA into both tumour and tumour-associated endothelial cells.